← FDA DRUG APPROVALS

FDA ANDA · ANDA077464

LAMIVUDINE

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA077464
TYPE
ANDA
ORIGINAL APPROVAL
2016-11-21
LATEST ACTION
2019-09-26
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LAMIVUDINEPrescription
LAMIVUDINE 150MG · TABLET · ORAL
LAMIVUDINEPrescription
LAMIVUDINE 300MG · TABLET · ORAL

Approval history

2019-09-26Labeling · Supplement 13 · standardAP
2019-09-26Labeling · Supplement 16 · standardAP
2019-09-26Labeling · Supplement 14 · standardAP
2016-11-21OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →